share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  05/06 08:34

Moomoo AI 已提取核心訊息

On May 1, 2024, TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company, announced a non-binding letter of intent to acquire a private company specializing in innovative CAR-T therapies for cancer treatment. The potential business combination involves a cash purchase price of $20 million, adjusted for the seller's indebtedness, and the issuance of American Depository Shares representing the company's ordinary shares. The total value attributable to the shares at closing is also set at $20 million. Additional payments are contingent upon the seller meeting various development milestones. The terms of the proposed transaction are subject to due diligence, negotiation, and execution of definitive agreements, as well as securing financing and necessary approvals. The acquisition aims to expand TC BioPharm's...Show More
On May 1, 2024, TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company, announced a non-binding letter of intent to acquire a private company specializing in innovative CAR-T therapies for cancer treatment. The potential business combination involves a cash purchase price of $20 million, adjusted for the seller's indebtedness, and the issuance of American Depository Shares representing the company's ordinary shares. The total value attributable to the shares at closing is also set at $20 million. Additional payments are contingent upon the seller meeting various development milestones. The terms of the proposed transaction are subject to due diligence, negotiation, and execution of definitive agreements, as well as securing financing and necessary approvals. The acquisition aims to expand TC BioPharm's therapeutic platform, particularly in the treatment of solid tumors and autoimmune diseases. The company's CEO, Bryan Kobel, expressed optimism about the synergies and benefits of the acquisition, which aligns with TC BioPharm's M&A strategy. However, there is no guarantee that the transaction will be completed as contemplated or at all.
2024年5月1日,處於臨床階段的生物技術公司TC BioPharm(Holdings)PLC宣佈了一份不具約束力的意向書,收購一家專門從事癌症治療創新CAR-T療法的私營公司。潛在的業務合併涉及經賣方債務調整後的2000萬美元現金收購價格,以及代表公司普通股的美國存托股票的發行。收盤時歸屬於股票的總價值也定爲2,000萬美元。額外付款視賣方是否滿足各種開發里程碑而定。擬議交易的條款需要經過盡職調查、談判和最終協議的執行,以及獲得融資和必要的批准。此次收購旨在擴大TC BioPharm的治療平台,特別是在實體瘤和自身免疫性疾病的治療方面。該公司首席執行官布萊恩·科貝爾對此次收購的協同效應和收益表示樂觀,這符合TC BioPharm的併購戰略。但是,無法保證交易會按預期完成或完全完成。
2024年5月1日,處於臨床階段的生物技術公司TC BioPharm(Holdings)PLC宣佈了一份不具約束力的意向書,收購一家專門從事癌症治療創新CAR-T療法的私營公司。潛在的業務合併涉及經賣方債務調整後的2000萬美元現金收購價格,以及代表公司普通股的美國存托股票的發行。收盤時歸屬於股票的總價值也定爲2,000萬美元。額外付款視賣方是否滿足各種開發里程碑而定。擬議交易的條款需要經過盡職調查、談判和最終協議的執行,以及獲得融資和必要的批准。此次收購旨在擴大TC BioPharm的治療平台,特別是在實體瘤和自身免疫性疾病的治療方面。該公司首席執行官布萊恩·科貝爾對此次收購的協同效應和收益表示樂觀,這符合TC BioPharm的併購戰略。但是,無法保證交易會按預期完成或完全完成。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息